Until now, experimentations focused on CD138+ augmented CTCs or on cfDNA for genetic analysis in MM patients have confirmed their usefulness for diagnosis, prognosis, and response evaluation [139]. This evidence concerns the gene SDC1 and Miyoshi myopathy.